Proteomics International has an unparalleled scientific and commercial team from a diverse range of backgrounds. The team has skills in all aspects of protein chemistry encompassing the cutting edge of mass spectrometry to traditional methods and more.
Richard has extensive experience in analysing biomolecules by proteomics techniques, in particular mass spectrometry, including over 25 years research experience in academic and commercial organisations. As a founding Director and Managing Director of Proteomics International Richard has overseen the commercial and technical development of the organisation. Previously he was Manager of the core Protein Analysis Facility at the University of Western Australia, following a post-doctoral position at the Institute for Child Health Research. He is company trained in the use of MALDI-TOF MS and LC/MS/MS (including TOF/TOFs and ion-traps), and further expertise/training in Edman sequencing, peptide synthesis, and robotics for proteomics.
1995 PhD (Immunology), University of London (Institute of Child Health)
1991 Certificate in Immunology, Kings College, University of London
1990 MA and BA (Chemistry), Corpus Christi College, Oxford University
Pearl joined Proteomics International in 2013, and is now responsible for managing the product development and commercialisation of PromarkerD, the company’s predictive diagnostic test for diabetic kidney disease.
Pearl has a background in Research, focusing on Biochemistry and Molecular Biology. She dedicated her career to the biotechnology industry following her involvement in an Industry-Research Collaboration (Researchers in Business Grant) between Proteomics International and UWA, to commercialise a patented technology for measuring oxidative stress.
2013 PhD (Research), Biochemistry and Molecular Biology, UWA
2008 BSc with honours in Biochemistry, UWA, Australia
2007 BSc, Molecular Biology and Biotechnology, UWA, Australia
Scott is responsible for all Research areas within Proteomics International. This involves oversight of Biomarker discovery and development projects encompassing PromarkerD, PI’s predictive test for diabetic nephropathy. Alongside the biomarker research program is the development and implementation of novel methods for examining biological systems (particularly venoms) for discovery of novel therapeutic peptides where genomic/ proteomic information is unavailable or incomplete. He also leads the development of new chromatographic and mass spectrometric methods for handling of complex biological samples for analysis and investigation.
Scott has a commercial background as proteomics scientist and mass spectrometry specialist at a New Zealand based R&D company, now part of AgResearch. This was preceded by a Post-Doctoral Fellowship at the National Cancer Institute, USA, looking at bioactive protein isolation, purification and identification of both anti-cancer and anti-HIV leads from marine sources. Scott’s skills are wide ranging and include expertise with mass spectrometers, liquid chromatography, assay development and bioinformatic analysis.
2001 PhD, Department of Chemistry, University of Canterbury
1997 BSc (Hons), Department of Chemistry, University of Canterbury
Kerryn joined Proteomics International in 2019 bringing an extensive research background in various diseases including muscle and neurodegenerative disorders, eye disease, cancers (prostate, colon, breast, lung, gynaecological and melanoma), using a wide range of molecular and genetic technologies. Her involvement in a diagnostic pathology service provider was to implement new technologies from research findings into routine diagnostic services providing patient management treatment decisions, and a strong engagement with clinical trial studies.
Kerryn’s background in the regulatory elements required for the translation of laboratory developed testing is strongly aligned with the focus of Proteomics International’s long-term visions for assay development and implementation worldwide. In addition, having provided technical assessor services to the accreditation agency NATA, she possesses a key set of expert skills that can be integrated into the management of the laboratory operations and overseeing the quality of laboratory output for both routine service provision and R&D project management.
2012 FFSc (RCPA) Fellowship Faculty of Science Royal College of Pathologists Australasia
1993 PhD University of Western Australia
1989 BSc (Hons) University of Western Australia
1988 BAppSc (Medical Laboratory Sciences) Curtin University
Chuck has over 36 years experience in life sciences, biotechnology, and diagnostic industries. Chuck has an undergraduate degree in chemistry and an MBA from Boston University. He has held several management positions while at NEN Life Sciences and DuPont before focusing his last 15 years in Business Development at PerkinElmer. Chuck has successfully executed many licensing deals and several global acquisitions while in this role. Chuck is based in Massachusetts, USA and started working with the Company in May 2014.
MBA, Boston University, Massachusetts, USA